Harmonizing the cardiovascular care of adult patients with cancer
- PMID: 37351594
- DOI: 10.1093/eurheartj/ehad267
Harmonizing the cardiovascular care of adult patients with cancer
Conflict of interest statement
Conflict of interest: T.L.F. received speaker and/or advisor fees from AstraZeneca, Bayer, Daiichi-Sankyo, Janssen, Philips, Myocardial Solutions, Beigene, all outside the submitted work. A.R.L received speaker, advisory board or consultancy fees, and/or research grants from Janssens-Cilag Ltd, Pfizer, Novartis, Servier, Astra Zeneca, Bristol Myers Squibb, GSK, Amgen, Takeda, Roche, Astellas Pharma, Clinigen Group, Eli Lily, Eisai Ltd, Ferring Pharmaceuticals, Boehringer Ingelheim, Akcea Therapeutics, Myocardial Solutions, iOWNA Health and Heartfelt Technologies Ltd.
Comment on
-
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244. Eur Heart J. 2022. PMID: 36017568 No abstract available.
-
A call for harmonized surveillance recommendations in cardio-oncology.Eur Heart J. 2023 Aug 14;44(31):3017-3018. doi: 10.1093/eurheartj/ehad268. Eur Heart J. 2023. PMID: 37350756 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical